#duchennewarriors
LightNews LightNews
dmdwarrior.com
Duchenne Muscular Dystrophy: Treatment & Cost

👉 Read and Share: dmdwarrior.com/duchenne-mus...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #elevidys #exonskipping #exon
Duchenne Muscular Dystrophy: Treatment & Cost - DMD Warrior
Learn about Duchenne Muscular Dystrophy (DMD), its early symptoms, current cures and treatment cost, gene therapies and the future of patients in the World.
dmdwarrior.com
January 2, 2025 at 12:33 PM
dmdwarrior.com
WE WILL FIGHT DUCHENNE and WE WILL WIN 💪

👉 dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna
dmdwarrior dmd warrior
December 28, 2024 at 6:39 PM
dmdwarrior.com
Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #musculardystrophy #gene #dna #mda
Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research
December 19, 2024 at 8:20 PM
dmdwarrior.com
No one cares about your child as much as you do. Together, we are stronger. 💪

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna
No one cares about your child as much as you do. Together, we are stronger. 💪 dmd warrior
December 27, 2024 at 7:46 PM
dmdwarrior.com
New Research on Duchenne Muscular Dystrophy Protein Interactions Lead to More Targeted Therapies

Read More: dmdwarrior.com/new-research...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #gene #dna #dystrophin #dystrobrevin
New Research on Duchenne Muscular Dystrophy Protein Interactions Lead to More Targeted Therapies Study results explain how dystrophin works molecularly, revealing how muscular dystrophy medicines can be developed. A pioneering discovery has shown the complicated relationships between dystrophin, a muscle stability protein, and its companion protein, dystrobrevin, opening new avenues for studying and treating Duchenne Muscular Dystrophy. Researchers describe dystrophin cryptic C-terminal (CT) region and its role in maintaining cellular membranes across tissues in the December Journal of Biological Chemistry. “This research highlights the intricate dynamics of dystrophin and dystrobrevin interactions, providing critical insights that could inform future treatment development,” said study lead author Krishna Mallela, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences professor. Our understanding of how these proteins work in diverse tissues is one step closer to finding DMD treatments that target the root causes.
January 1, 2025 at 9:51 AM
dmdwarrior.com
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #dyne #dyne251 #dyne101
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics Dyne Therapeutics announces clinical trial plans for DYNE-101 and DYNE-251, targeting myotonic dystrophy and Duchenne muscular dystrophy. Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg/kg Q8W and a potential U.S. Accelerated Approval submission in H1 2026. Meanwhile, DYNE-251, targeting Duchenne muscular dystrophy (DMD), is also pursuing U.S. Accelerated Approval based on dystrophin as a surrogate endpoint, with data expected by late 2025 to support an early 2026 submission. Both programs show promise in transforming treatment paradigms for these genetic diseases.
January 10, 2025 at 2:07 PM
dmdwarrior.com
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

What other new gene therapy studies are there besides Elevidys?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #newgenetherapies
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy What other new gene therapy studies are there besides Elevidys? Let’s remember the new gene therapies that will be an alternative to Elevidys.
January 5, 2025 at 11:51 AM
dmdwarrior.com
Dr. Jason Pugh studies cognitive deficits in Duchenne muscular dystrophy 🧠 Research at UT Health San Antonio

Learn more: news.uthscsa.edu/trailblazing...

#dmd #genetherapy #dmdwarrior #dmdwarriors
#duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #brain
Dr. Jason Pugh studies cognitive deficits in Duchenne muscular dystrophy Dr. Jason Pugh studies cognitive deficits in Duchenne muscular dystrophy Dr. Jason Pugh studies cognitive deficits in Duchenne muscular dystrophy Dr. Jason Pugh studies cognitive deficits in Duchenne muscular dystrophy
November 21, 2024 at 1:18 PM
dmdwarrior.com
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #Capricor #Deramiocel #fda
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy. -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku.
January 2, 2025 at 7:40 PM
dmdwarrior.com
Vamorolone (Agamree) Approved in Scotland

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #agamree #vamorolone #santhera #scotland #uk #england
Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.
January 13, 2025 at 3:36 PM
dmdwarrior.com
Zebrafish Modeling Shows Promise in Duchenne (DMD) Research

Read More: dmdwarrior.com/zebrafish-mo...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #zebrafish #crispr #crisprcas9
Zebrafish Modeling Shows Promise in Duchenne (DMD) Research Zebrafish (Danio rerio) has emerged as a valuable model organism for investigating musculoskeletal development and the pathophysiology of associated diseases. Key genes and biological processes in zebrafish are very similar to those in humans, and the rapid development and transparent embryos make zebrafish ideal for in vivo studies of bone and muscle formation as well as the molecular mechanisms underlying musculoskeletal disorders. Research is focusing on the utility of zebrafish in modeling various musculoskeletal disorders, with particular emphasis on bone diseases such as osteoporosis and osteogenesis imperfecta, and muscle disorders such as Duchenne muscular dystrophy.
December 30, 2024 at 4:11 PM
dmdwarrior.com
FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #exon51 #exon51skipping #nipponshinyaku #exonskipping
FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04) Nippon Shinyaku declared that NS-051/NCNP-04, a medication being developed to treat Duchenne Muscular Dystrophy (DMD), has been granted Rare Pediatric Disease Designation by the Food and Drug Administration (FDA). Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051/NCNP-04. By omitting a portion of the dystrophin gene’s genetic material, NS-051/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function.
January 23, 2025 at 12:11 PM
dmdwarrior.com
Is Duchenne Gene Therapy a Suitable Treatment Despite its Immunogenic Class Effect?

Read More: dmdwarrior.com/is-duchenne-...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna
Is Duchenne Gene Therapy a Suitable Treatment Despite its Immunogenic Class Effect? This article will examine current gene therapies up to August 2024, including micro-dystrophin Duchenne therapies and CRISPR-Cas9 therapies found on ClinicalTrials.gov. Progressive muscle weakness and eventual mortality as a result of cardiomyopathy or respiratory complications are the hallmarks of Duchenne muscular dystrophy (DMD), a severe X-linked disorder. At present, there is no cure for DMD, and the primary focus of standard treatments is on symptom management. Gene therapies can more effectively address the genetic cause of the disease by employing immunosuppressive measures and optimized vector designs. What are the effects of gene therapy treatments in Duchenne muscular dystrophy (DMD) disease, do gene therapies work? Here is a comprehensive analysis.
January 1, 2025 at 11:11 PM
dmdwarrior.com
Together, we are stronger. 💪

Happy New Year
dmdwarrior.com❤️#dmd##duchennee#bmd##beckerc#genetherapyr#dmdwarriorr#dmdwarriorsi#duchennewarriorsio#duchennee#duchenneheroesr#musculardystrophyo#geneg#dna##newyeary#happynewyearyear #2#christmast#worldo#followmeowme
As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com As we step into this new year, we want to send all our love and warmest wishes to you. May this year bring moments of joy, hope, and strength, no matter the challenges you may face. You are so brave, and your spirit inspires everyone around you. To the family: Your love, care, and support mean the world, and together, you make an incredible team. May the year ahead be filled with laughter, treasured memories, and new milestones, no matter how small they may seem. Keep believing in the power of hope and never forget how strong you are as a family. Here's to a year of courage, love, and endless possibilities. Together, we are stronger. 💪 With love and hope, dmdwarrior.com
December 30, 2024 at 7:34 PM
dmdwarrior.com
Will Elevidys Receive Approval from the European Medicines Agency (EMA)?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #roche @roche #elevidys #sarepta
Will Elevidys Receive Approval from the European Medicines Agency (EMA)? Patients with Duchenne muscular dystrophy (DMD) around Europe are anxiously awaiting the EMA's approval of Sarepta's application for its gene treatment Elevidys. Will Elevidys Receive Approval from the European Medicines Agency (EMA)? 📌 In Which Countries Is Elevidys Approved? 📌 In Which Countries Has Roche Applied for Authorization for Elevidys? 📌 Interim Results from Elevidys’ Embark Clinical Trial Could Impact Decision 📌 Why Are Sarepta and Roche Only Applying for Registration in Certain Countries? 📌 Families Concern if Sarepta for a Different Gene Therapy Will Not Be Approved by EMA 📌 Genethon and Sarepta Collaborated in 2017 📌 Pricing Policies Should Be Revised
January 29, 2025 at 8:48 AM
dmdwarrior.com
WE WILL FIGHT DUCHENNE and WE WILL WIN 💪

👉 dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna
dmd warrior dmdwarrior
January 23, 2025 at 9:13 PM
dmdwarrior.com
Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #gene #dna #beliefbiomed #BBMD101 #china #shanghai
Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101 The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for Belief BioMed’s (BBM) Duchenne Muscular Dystrophy (DMD) gene therapy candidate, BBM-D101. BBM is a forward-thinking biotechnology company that focuses on creating innovative gene therapies.
January 23, 2025 at 8:14 PM
dmdwarrior.com
What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy?

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #bobcat #mrna #bobcatmrna
What is Bobcat mRNA? How Does Bobcat mRNA Work for Duchenne Muscular Dystrophy? What is Bobcat mRNA? Bobcat mRNA is a proprietary linear mRNA technology that produces high-quality mRNA encoding large proteins (greater than 13 kb) in a highly efficient and cost-effective manner. A lipid nanoparticle (LNP) delivers it. Elixirgen Therapeutics is first looking into how Bobcat mRNA can be used with dystrophin, which is the largest human gene known.
January 21, 2025 at 2:03 PM
dmdwarrior.com
Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #insmed #ins1201
Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD) For its INS1201 Duchenne (DMD) gene therapy, Insmed intends to initiate Phase I clinical trials in the first part of the year 2025. Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials for INS1201 in the first half of 2025 after the FDA approved its investigational new drug (IND) application in December 2024. What is Insmed INS1201 Gene Therapy? Learn More: dmdwarrior.com
January 16, 2025 at 10:59 AM
dmdwarrior.com
Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #gene #dna #solidbiosciences #sgt003
Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy Solid Biosciences shared detailed information about the clinical trials of its SGT-003 Gene Therapy developed for the treatment of Duchenne Muscular Dystrophy. Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.
January 16, 2025 at 9:22 AM
dmdwarrior.com
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #agamree #vamorolone #santhera #Clinigen #clinigengroup
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.
January 6, 2025 at 12:14 PM
dmdwarrior.com
One day our children will be able to enjoy life freely.

Together, we are stronger. 💪

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #musculardystrophy #gene #dna #newyear #snowboarding #2025 #skiing #world #followme
One day our children will be able to enjoy life freely. dmd warrior. dmdwarrior.
January 3, 2025 at 7:24 PM
dmdwarrior.com
Genethon Expects to Begin Phase 3 Trials of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy in 2025 in Europe, Followed by US

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #gene #dna #genethon #gnt0004 #europe #2025
Genethon Expects to Begin Phase 3 Trials of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy in 2025 in Europe, Followed by US
December 19, 2024 at 8:19 PM
dmdwarrior.com
Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Source: www.novartis.com/stories/addr...

#dmd #bmd #genetherapy #dmdwarrior #dmdwarriors
#duchennemusculardystrophyawareness #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #novartis
Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy
November 24, 2024 at 10:02 AM